Only in Titles

           Search results for: Mouse Anti-Human Endothelial Cells Antibodies    

paperclip

#28384052   // Save this To Up

PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.

Podocalyxin (PODXL) is a CD34-related sialomucin and a well-known marker of embryonic stem cells. PODXL is expressed in many types of tumors including colorectal cancers, breast cancers, and brain tumors. Overexpression of PODXL is an independent predictor of progression, metastasis, and poor outcome. PODXL is also expressed in many normal cells such as renal podocytes and endothelial cells (ECs). However, high-sensitive and high-specific anti-PODXL monoclonal antibodies (mAbs) have not been established. Herein, we immunized mice with recombinant human PODXL, which was produced using LN229 glioblastoma cells. The anti-PODXL mAb, PcMab-47, reacted with endogenous PODXL-expressing cancer cell lines and normal cells independently of glycosylation in flow cytometry. Immunohistochemical analysis showed that PcMab-47 detected PODXL-expressing normal cells such as podocytes of kidney or ECs. Furthermore, PcMab-47 stained PODXL-expressing cancer cells of colon or breast cancers. These results suggest that PcMab-47 could be useful for investigating the expression and function of PODXL in cancers and normal tissues.

1179 related Products with: PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.

MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI BORRELIA BURGD MOUSE ANTI CANINE DISTEMP MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD19 RPE MOUSE ANTI APAAP COMPLEX, MOUSE ANTI HUMAN CD15, Pr Anti AGO2 Mouse, Monoclon Anti-AVP Monoclonal Antib HSV2 gC antibody, Monoclo Anti-aminopeptidase N Mon Monoclonal Anti-Biotin-Pe

Related Pathways

paperclip

#28332312   // Save this To Up

Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

Human podoplanin (hPDPN), a platelet aggregation-inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C-type lectin-like receptor 2 (CLEC-2). The overexpression of hPDPN is involved in invasion and metastasis. Anti-hPDPN monoclonal antibodies (mAbs) such as NZ-1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation-stimulating (PLAG) domain of hPDPN. Recently, we developed a novel mouse anti-hPDPN mAb, LpMab-2, using the cancer-specific mAb (CasMab) technology. In this study we developed chLpMab-2, a human-mouse chimeric anti-hPDPN antibody, derived from LpMab-2. chLpMab-2 was produced using fucosyltransferase 8-knockout (KO) Chinese hamster ovary (CHO)-S cell lines. By flow cytometry, chLpMab-2 reacted with hPDPN-expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab-2 exhibited high antibody-dependent cellular cytotoxicity (ADCC) against PDPN-expressing cells, despite its low complement-dependent cytotoxicity. Furthermore, treatment with chLpMab-2 abolished tumor growth in xenograft models of CHO/hPDPN, indicating that chLpMab-2 suppressed tumor development via ADCC. In conclusion, chLpMab-2 could be useful as a novel antibody-based therapy against hPDPN-expressing tumors.

2325 related Products with: Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

MOUSE ANTI HUMAN CD15, Pr anti CD20 monoclonal anti MOUSE ANTI HUMAN CD15, Pr Rabbit Anti-Nkx2.5 Cardia Rabbit Anti-IEX1 Differen MOUSE ANTI HUMAN CD19 RPE PABP1-dependent poly A-sp Rabbit Anti-IEX1 Differen Anti-Human , Mouse Monocl Inflammation (Mouse) Anti JAK2(Phospho-Tyr221) Anti Mouse Monoclonal Antibody

Related Pathways

paperclip

#26852859   // Save this To Up

Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes.

Surface functionalization with antitransferrin receptor (TfR) mAbs has been suggested as the strategy to enhance the transfer of nanoparticles (NPs) across the blood-brain barrier (BBB) and to carry nonpermeant drugs from the blood into the brain. However, the efficiency of BBB crossing is currently too poor to be used in vivo. In the present investigation, we compared 6 different murine mAbs specific for different epitopes of the human TfR to identify the best performing one for the functionalization of NPs. For this purpose, we compared the ability of mAbs to cross an in vitro BBB model made of human brain capillary endothelial cells (hCMEC/D3). Liposomes functionalized with the best performing mAb (MYBE/4C1) were uptaken, crossed the BBB in vitro, and facilitated the BBB in vitro passage of doxorubicin, an anticancer drug, 3.9 folds more than liposomes functionalized with a nonspecific IgG, as assessed by confocal microscopy, radiochemical techniques, and fluorescence, and did not modify the cell monolayer structural or functional properties. These results show that MYBE/4C1 antihuman TfR mAb is a powerful resource for the enhancement of BBB crossing of NPs and is therefore potentially useful in the treatment of neurologic diseases and disorders including brain carcinomas.

2905 related Products with: Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes.

Rabbit Anti-Rat Calcitoni Goat Anti- TACR2 Neurokin Rat Anti-CCT theta Antibo Goat Anti-Human Neuropept Rabbit Anti-Dopamine D1 R Rabbit Anti-Dopamine D5 R IGF-1R Signaling Phospho- Goat Anti-Human Histamine Rabbit Anti-Rat GABA A Re Rat monoclonal anti mouse Mouse anti human IGF-I Re Sheep Anti-Human Estrogen

Related Pathways

paperclip

#24447619   // Save this To Up

Imaging of CD47 expression in xenograft and allograft tumor models.

CD47 functions as a marker of "self" by inhibiting phagocytosis of autologous cells. CD47 has been shown to be overexpressed by various tumor types as a means of escaping the antitumor immune response. The goal of this research was to investigate the utility of CD47 imaging using positron emission tomography (PET) in both human xenograft and murine allograft tumor models. Anti-CD47 antibodies were conjugated with p-isothiocyanatobenzyldesferrioxamine (Df-Bz-NCS) and labeled with 89Zr. We employed xenograft and allograft small-animal models of cancer in biodistribution and PET imaging studies to investigate the specificity and PET imaging robustness of CD47. Ab-Df-Bz-NCS conjugates were labeled with 89Zr with specific activity of 0.9 to 1.6 μCi/μg. Biodistribution studies in the xenograft and allograft model showed similar specific tumor uptake of the antihuman and antimouse CD47 antibodies. However, the tracer retention in the liver, spleen, and kidneys was significantly higher in the allograft-bearing animals, suggesting uptake mediated by the CD47 normally expressed throughout the reticular endothelial system. CD47, a marker of "self," was evaluated as a diagnostic PET biomarker in xenograft and allograft cancer animal models. CD47 imaging is feasible, warranting further studies and immunoPET tracer development.

2302 related Products with: Imaging of CD47 expression in xenograft and allograft tumor models.

Breast tumor survey tissu Breast tumor survey tissu Multiple organ tumor tiss Breast tumor survey tissu Skin tumor tissue array, Multiple organs tumor and Colon tumor test tissue a Colon tumor survey tissue Multiple organ tumor and Skin tumor tissue array, Breast tumor survey tissu Heart tumor test tissue a

Related Pathways

paperclip

#24337602   // Save this To Up

Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

This study evaluates targeted liposomes loaded with the α-particle generator (225)Ac to selectively kill prostate-specific membrane antigen (PSMA)-expressing cells with the aim to assess their potential for targeted antivascular radiotherapy.

1761 related Products with: Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

Prostate cancer, hyperpla Mouse Anti-Prostate Speci MOUSE ANTI BORRELIA BURGD Prostate cancer tissue ar Prostate cancer frozen ti PSA (Prostate Specific A MOUSE ANTI HUMAN CD19 RPE PSA (Prostate Specific A Prostate cancer tissue ar PSA (Prostate Specific A Prostate cancer tissue ar Mouse Anti-Ca19.9 Sialyl

Related Pathways

paperclip

#22551544   // Save this To Up

Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

In patients, a transient decrease in peripheral blood lymphocyte counts was observed following intraperitoneal administration of the trifunctional monoclonal antibody catumaxomab (anti-human EpCAM x anti-human CD3). The aim of this study was to clarify the observed effect in a preclinical mouse model and to analyse the related mechanism of action in vitro.

2612 related Products with: Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

FDA Standard Frozen Tissu Oral squamous cell cancer Mouse Anti-Human CD103 (I Goat Anti-Human XBP1 TREB FDA Standard Frozen Tissu Rabbit Anti-Human Toll In Mouse Anti-Human CD103 (I Goat Anti-Human Factor XI Goat Anti-Human TOM1L1 SR Goat Anti-Human Ku80 XRCC Goat Anti- ABCF3, (intern Goat Anti- LASS5+6 CerS5+

Related Pathways

paperclip

#21309681   // Save this To Up

E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.

E-selectin is an attractive endothelial cell surface marker in inflammation and cancer.

2392 related Products with: E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.

Human Umbilical Vein Endo Human Internal Mammary Ar Mitochondria GFP Tag Huma RFP Expressing Human Umbi GFP Expressing Human Umbi GFP Expressing Human Inte Mouse Anti-Human Endothel Plasma Membrane GFP Tag H Rabbit Anti-TNIP2 ABIN2 T Goat Anti-Human Nur77 TR3 Anti AGO2 Human, Monoclon MOUSE ANTI HUMAN CD15, Pr

Related Pathways

paperclip

#19719773   // Save this To Up

Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.

Angiogenesis plays a crucial role in cancer progression and metastasis. Thus, blocking tumor angiogenesis is potentially a universal approach to prevent tumor establishment and metastasis. In this study, we used in vivo and ex vivo fluorescence imaging to show that an antihuman vascular endothelial growth factor (VEGF) antibody represses angiogenesis and the growth of primary tumors of human fibrosarcoma HT1080 cells in implanted nude mice. Interestingly, administering the antihuman VEGF antibody reduced the development of new blood vessels and normalized pre-existing tumor vasculature in HT1080 cell tumors. In addition, antihuman VEGF antibody treatment decreased lung metastasis from the primary tumor, whereas it failed to block lung metastasis in a lung colonization experiment in which tumor cells were injected into the tail vein. These results suggest that VEGF produced by primary HT1080 cell tumors has a crucial effect on lung metastasis. The present study indicates that the in vivo fluorescent microscopy system will be useful to investigate the biology of angiogenesis and test the effectiveness of angiogenesis inhibitors.

2511 related Products with: Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.

Rabbit Anti-intestinal FA Angiogenesis (Human) Anti Anti AGO2 Human, Monoclon Brain-Specific Angiogenes Anti-human C1 Esterase In Rabbit Anti-APIP Apaf1 In Goat Anti-Human Fibroblas Rabbit Anti-TNIP2 ABIN2 T Rabbit Anti-Cell death in Anti beta3 AR Human, Poly Anti-human C1 Esterase In Multiple organ tumor tiss

Related Pathways

paperclip

#19706815   // Save this To Up

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.

The biological effect of interleukin-6 (IL-6) signaling in oral squamous cell carcinoma (OSCC) and whether IL-6 receptor (IL-6R)-mediated signaling can be a therapeutic target for OSCC are unclear. The aim of this study was to investigate the effects of inhibition of IL-6R-mediated signaling on OSCC progression and to evaluate the availability of tocilizumab, a humanized antihuman IL-6R antibody, as a therapeutic agent for OSCC.

1910 related Products with: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.

Oral squamous cell cancer Rabbit Anti-TNIP2 ABIN2 T Rabbit Anti-Cell death in interleukin 17 receptor C Esophageal squamous cell Oral cavity squamous cell Esophageal squamous cell Rabbit Anti-TNIP2 ABIN2 T Rabbit Anti-Cell death in Mouse Anti-Human Interleu Rabbit Anti-APIP Apaf1 In Lung squamous cell carcin

Related Pathways

paperclip

#18224682   // Save this To Up

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

In the present study, we investigated the mechanisms by which anti-endoglin (EDG; CD105) monoclonal antibodies (mAbs) suppress angiogenesis and tumor growth. Antihuman EDG mAb SN6j specifically bound to murine endothelial cells and was internalized into the cells in vitro. SN6j effectively suppressed angiogenesis in mice in the Matrigel plug assay. We found that SN6j is more effective for tumor suppression in immunocompetent mice than in SCID mice. We hypothesized that T cell immunity is important for effective antitumor efficacy of SN6j in vivo. To test this hypothesis, we investigated effects of CpG oligodeoxynucleotides (ODN) and depletion of CD4(+) T cells and/or CD8(+) T cells on antitumor efficacy of SN6j in mice. Systemic (i.v.) administration of a relatively small dose (0.6 mug/g body weight/dose) of SN6j suppressed growth of established s.c. tumors of colon-26 in BALB/c mice and improved survival of the tumor-bearing mice. Addition of CpG ODN to SN6j synergistically enhanced antitumor efficacy of SN6j. In contrast, such enhancing effects of CpG ODN were not detected in SCID mice. Antitumor efficacy of SN6j in BALB/c mice was abrogated when CD4(+) T cells and/or CD8(+) T cells were depleted; effect of CD8(+) T cell depletion was stronger. Interestingly, CD4-depletion decreased tumor growth while CD8-depletion enhanced tumor growth in the absence of SN6j. SN6j induced apoptosis in human umbilical vein endothelial cells in a dose-dependent manner which indicates an additional mechanism of antiangiogenesis by SN6j. (c) 2008 Wiley-Liss, Inc.

2989 related Products with: Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Anti AGO2 Mouse, Monoclon Mouse Anti-Insulin(1D4:) Anti AGO2 Human, Monoclon Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1D4:) Anti AGO2 Human, Monoclon Mouse Anti-Insulin(1D4:) Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1D4:) Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1D4:) Anti AGO2 Mouse, Monoclon

Related Pathways